“Treat-to-Target” in Systemic Lupus Erythematosus: Novel Definitions of Remission and Low Disease Activity
PDF BG (Български)
PDF ENG

Keywords

Systemic lupus erythematosus (SLE); Disease activity; Treat-to-target (T2T)

How to Cite

Pencheva, D., Bakalov, D., Boyadzhieva, V., Ivanova, M., & Stoilov, N. (2024). “Treat-to-Target” in Systemic Lupus Erythematosus: Novel Definitions of Remission and Low Disease Activity. Rheumatology (Bulgaria), 32(3), 63-77. https://doi.org/10.35465/32.3.2024.pp63-77

Abstract

Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with alternating periods of activity and remission, where an accurate assessment of disease activity remains crucial for optimal treatment. For this purpose, various instruments and composite measures have been developed to enable objective evaluation and effective patient monitoring. In recent years, the SLE Disease Activity Score (SLE-DAS), validated in 2019, has emerged as a reliable and precise method. It combines 17 clinical and laboratory parameters, offering a more accurate assessment of disease activity. Furthermore, SLE-DAS defines clear criteria for remission and low disease activity, supporting the “treat-to-target” approach. Despite the significance of SLE-DAS, other scales such as the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and its modified versions, Systemic Lupus Activity Measure (SLAM), SLAQ (Systemic Lupus Activity Questionnaire), and the British Isles Lupus Assessment Group (BILAG) Index—continue to be used in clinical practice. Of these, SLEDAI-2K remains the most frequently employed tool in daily rheumatological practice. Despite the variety of tools available, SLE-DAS stands out for its precision, practicality, and wide applicability, both in routine clinical practice and clinical trials, emphasizing its broad utility in managing SLE.

https://doi.org/10.35465/32.3.2024.pp63-77
PDF BG (Български)
PDF ENG

References

  1. Kaul A, Gordon C, Crow MK et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16;2:16039.
  2. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major
  3. contributors. Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v29-v38.
  4. Arnaud L, Parodis I, Devilliers H et al. Clinical trial outcomes for SLE: what we have and what we need. Lupus Sci Med. 2024 Feb 15;11(1):e001114.
  5. Cruciani C, Zen M, Gatto M et al. Assessment of disease activity and damage in SLE: Are we there yet? Best Practice & Research Clinical Rheumatology, 2023,37(4),101896.
  6. Gordon C, Amissah-Arthur MB, Gayed Met et al. The British Society for Rheumatology guideline for themanagement of systemic lupus erythematosus in adults, Rheumatology, 2018,57(1),e1- e45.
  7. Jesus D, Rodrigues M, Matos A et al. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36- month prospective cohort study of 334
  8. patients. Lupus 2019;28(5):607-12.
  9. Jesus D, Matos A, Henriques C et al. Derivation and validationof the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. AnnRheum Dis. 2019;78:365–371.
  10. Jesus D, Larosa M, Henriques C et al. Systemic LupusErythematosus Disease Activity Score (SLE-DAS) enables accurateand user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis 2021;80:1568-74.
  11. Van Vollenhoven RF, Mosca M, Bertsias G et al Treat to-target insystemic lupus erythematosus: recommendations fromaninternational task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139.
  12. Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022 Mar;18(3):146-157.
  13. Fanouriakis A, Kostopoulou M, Andersen J et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update Annals of the RheumaticDiseases 2024;83:15-29.
  14. Strand V, Gladman D, Isenberg D et al. Endpoints: consensus recommendations from OMERACT IV. Lupus 2000;9:322-7.
  15. Liang MH, Socher SA, Larson MG et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989Sep;32(9):1107-1118
  16. Chessa E, Piga M, Arnaud L. Physician global assessment insystemic lupus erythematosus: can we rely on its reliability? AnnRheum Dis. 2022 May;81(5):e79.
  17. Dall’Era M, Bruce IN, Gordon C et al. Current challenges inthedevelopment of new treatments for lupus. Ann RheumDis 2019;78(6):729-35.
  18. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992;35:630-640.
  19. Gladman DD, Urowitz MB, Kagal A et al. Accurately describingchanges in disease activity in systemic lupus erythematosus. JRheumatol. 2000 Feb;27(2):377-379.
  20. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006;33:1570-1577.
  21. Petri M, Kim MY, Kalunian KC et al. Combinedoral contraceptives in women with systemic lupus erythematosus. NEngl J Med. 2005 15; 353(24)2550–2558.
  22. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosusdisease activity index 2000. J Rheumatol.
  23. ;29(2):288–291.
  24. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med.
  25. ;86(7):447–458.
  26. Touma Z, Urowitz MB, Ibañez D et al. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011 Jan;20 (1):67–70.
  27. Touma Z, Gladman DD, Su J et al. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K
  28. glucocorticoid index. Rheumatology (Oxford). 2018 Aug;57(8):1370–1376.
  29. Bae SC, Koh HK, Chang DK et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus. 2001;10(6):405–409.
  30. Karlson E, Daltroy L, Rivest C et al.Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280-6.
  31. Chehab G, Richter J, Sander O et al Validation and evaluation of the German version of the Systemic Lupus Activity Questionnaire (SLAQ). Clin Exp Rheumatol. 2015 May Jun;33(3):354-9.
  32. Symmons DP, Coppock JS, Bacon PA et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988 Nov;69(259):927–937.
  33. Isenberg DA, Rahman A, Allen E et al. BILAG 2004. development and initial validation of an updated version of the British isles lupus assessment group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:902–6.
  34. Carter LM, Gordon C, Yee C-S et al. Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology (Oxford). 2022 Jan;61(10):4006–4015.
  35. Abdelhady EI, Rabie M, Hassan RA. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS). Clin Rheumatol. 2021 Nov;40(11):4553–4558.
  36. Lai, NS, Lu MC, Chang HH et al. Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health- Related Quality of Life. J. Clin. Med. 2021,10,2137.
  37. Onishi A, Tsuji H, Takase Y et al. Comparisons of SLEDAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-ported outcomes. Rheumatology (Oxford). 2023 Dec 1;62(12):3909-3915.
  38. Larosa M, Costedoat-Chalumeau N, Guettrot-Imbert G et al. SLE-DAS in the first trimester of gestation predicts maternal lupusflares later in pregnancy. Front Pharmacol; 12.
  39. Pencheva D, Monov S. P112 Association of lupus low disease activity with health-related quality of life: Lupus Science & Medicine 2024;11.
  40. Mucke J, Kuss O, Brinks R et al. LUPUS- BEST-treat-totarget in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial. Lupus Sci Med. 2021 Jul;8(1):e000516.
  41. van Vollenhoven RF, Bertsias G, Doria A et al 2021 DORIS definition of remission in SLE: final recommendations from an international task force Lupus Science & Medicine 2021;8.
  42. Franklyn K, Lau CS, Navarra SV et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) Annals of the Rheumatic Diseases 2016;75:1615-1621.
  43. Morand EF, Fernandez-Ruiz R, Blazer A et al. Advances in the management of systemic lupus erythematosus. BMJ. 2023 Oct 26;383:e073980.
  44. Golder V, Kandane-Rathnayake R, Hoi AY et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017 Mar 20;19(1):62.
  45. Golder V, Kandane-Rathnayake R, Huq M et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019 Oct 1; 1(2)e95–102.
  46. Morand EF, Trasieva T, Berglind A et al. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018 May;77(5):706– 713.
  47. Assunção H, Jesus D, Larosa M et al. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford). 2022 Aug 3;61(8):3309-3316.
  48. Jesus, D, Henriques C, Matos A et al. SLE-DAS remission and low disease activity states discriminate drug from placebo and better health-related quality of life. Arthritis Care Res 2024, 76: 788-795
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.